Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“Another milestone in our BCG Naive randomized trial (QUILT-2.005) reached in which 50% of enrolled patients reached an evaluable time point for efficacy, triggering an Independent Data Monitoring Committee (IDMC) review to evaluate statistical power of the adequacy of the sample size (N=366) to detect clinically meaningful differences between ANKTIVA plus BCG versus BCG alone.
Determination by IDMC of whether we need to enroll more patients or whether the 366 completely enrolled is sufficient to detect the pre-specified clinically meaningful differences between the two arms. Stay tuned.
Our hypothesis that IL-15 is a key immunotherapy cytokine and the quest continues.”
Other articles featuring Patrick Soon-Shiong on OncoDaily.